Companies · Healthtech
SAN MATEO · KA, India; Remote · Healthtech · refined from filed group “Other Technology” · founded 2021 · https://zealth-ai.com/
Diligence memoA one-page analyst read on Zealth, Inc. — recommendation, valuation, rhythm, risks.→Zealth, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the healthtech sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Zealth, Inc. is one of 2138 Healthtech companies tracked from SAN MATEO, KA, India; Remote, on record since 2021. By capital raised it ranks among the largest (ahead of 96% of sector peers), and among the largest by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
Software for remote monitoring of cancer patients
Zealth is building remote monitoring software to help hospitals provide automated continuous round-the-clock support to their cancer patients post-discharge. Hospitals are overburdened with no resources to provide care to their chronic patients once they leave the hospital. For instance, in India, there are only 2200 oncologists for 1.38 billion people. Patients travel 100 miles waiting for hours to get few minutes with the doctors. They have no easy means to manage all the toxicities and symptoms they get once they are back home. This leads to 6X lower patient retention, 4X high emergency readmissions, and poor patient outcomes. Zealth bridges this gap through its digital health intervention platform.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 20%.
Round size and date are reported; the stage label is inferred from round size (latest is Series C — a $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the healthtech sector profile. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 2138 companies in Healthtech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 96% of sector peers (real $). Modeled value above 99% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #4 of 33.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Virta Health Corp. | Series C | $122.0M | $2.4B | 2.19× |
| Fresenius Medical Care Voorhees, LLC | Series C | $71.1M | $1.8B | 1.67× |
| Clear Health Pass Holdings LLC | Series C | $100.0M | $1.8B | 1.67× |
| Zealth, Inc. this company | Series C | $95.0M | $1.7B | 1.55× |
| Jawbone Health Hub, Inc. | Series C | $65.4M | $1.7B | 1.54× |
| Boston Health Economic Holdings, LLC | Series C | $63.0M | $1.6B | 1.48× |
| PWN Health Holdings, Inc. | Series C | $61.8M | $1.5B | 1.39× |
| Quartet Health, Inc. | Series C | $127.0M | $1.4B | 1.28× |
| Workit Health, Inc. | Series C | $87.9M | $1.4B | 1.27× |
| Ajax Health II LLC | Series C | $51.0M | $1.3B | 1.20× |
| Eden Health, Inc. | Series C | $73.4M | $1.3B | 1.19× |
| NeuSpera Medical Inc. | Series C | $88.6M | $1.3B | 1.19× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Series C | $95.0M | 2021-10-27 | $633.3M | $1.7B | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Carl Byers | — | 6 other | 2021-10 |
| Justin White | — | 2 other | 2021-10 |
| Adam Ting | — | — | 2021-10 |
| Pranay Kapadia | — | — | 2021-10 |
Zealth, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Quartet Health, Inc. | Healthtech | Series C | $127.0M | $1.4B | network1 shared operator · same sector · same stage |
| Akura Medical, Inc. | Healthtech | Series C | $94.8M | $299.4M | same sector · same stage |
| Magnolia Medical Technologies, Inc. | Healthtech | Series C | $94.2M | $727.7M | same sector · same stage |
| Elevate Care International Topco LP | Healthtech | Series C | $98.4M | $1.0B | same sector · same stage |
| Clear Health Pass Holdings LLC | Healthtech | Series C | $100.0M | $1.8B | same sector · same stage |
| Freedom Dental Funding, LLC | Healthtech | Series C | $100.0M | $1.1B | same sector · same stage |
| Genome Medical Holding Co | Healthtech | Series C | $90.0M | $605.8M | same sector · same stage |
| HighFive Healthcare TopCo, LLC | Healthtech | Series C | $100.7M | $600.8M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Spire Health Remote patient monitoring for lung disease patients. | Medical Devices | — | — | 76% |
| Clinikally India's Telemedicine Platform & Online Pharmacy for Dermatology Care | Healthtech | — | — | 76% |
| Transradial Technologies, Inc. | Software / Tech | Pre-Seed | $1.4M | 76% |
| Zeal Analytics, Inc. | Software / Tech | Pre-Seed | $6.1M | 75% |
| Life Detection Technologies, Inc. | Software / Tech | Seed | $5.1M | 74% |
| JenaValve Technology Inc | Software / Tech | Series D+ | $2.2B | 74% |
| Zea Health, Inc. | Healthtech | Seed | $7.3M | 74% |
| Zakipoint Health, Inc. | Healthtech | Seed | $13.9M | 73% |
See where Zealth, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Zealth, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.